Based on immunohistochemistry showing CD117 positive, DOG-1 positive, HMB45 negative, MELAN‑A/MART‑1 negative, and SOX10 positive, what is the most likely diagnosis and recommended treatment plan?

Diagnosis: Gastrointestinal Stromal Tumor (GIST)

Based on the immunohistochemistry profile showing CD117 positive, DOG-1 positive, HMB45 negative, MELAN-A/MART-1 negative, and SOX10 positive, the most likely diagnosis is a gastrointestinal stromal tumor (GIST), and the patient requires immediate molecular testing for KIT and PDGFRA mutations to guide treatment decisions.

Diagnostic Interpretation

The immunohistochemical pattern is diagnostic for GIST:

• CD117 (positive) and DOG-1 (positive): This combination is pathognomonic for GIST, with both markers showing 94-96% sensitivity 1, 2. The dual positivity essentially confirms the diagnosis, as approximately 95% of GISTs express CD117 and 91% express DOG-1 3, 4.

• HMB45 (negative), MELAN-A/MART-1 (negative): These negative melanocytic markers effectively exclude melanoma from the differential diagnosis. While the SOX10 positivity might initially raise concern for melanoma, the absence of HMB45 and MELAN-A combined with strong CD117/DOG-1 positivity makes melanoma extremely unlikely.

• SOX10 (positive): This is an unusual but documented finding in GISTs. While SOX10 is typically associated with melanocytic and neural crest tumors, it can occasionally be expressed in GISTs and does not contradict the diagnosis when CD117/DOG-1 are strongly positive.

Critical Next Steps

Mandatory Molecular Testing

Molecular analysis for KIT and PDGFRA mutations must be performed immediately 1, 2. This is not optional—it is essential for:

1. Treatment planning: 80-85% of GISTs harbor activating mutations (primarily KIT exon 11 and exon 9) that predict response to imatinib (Gleevec)
2. Prognostic stratification: Specific mutations carry different prognostic implications
3. Identifying imatinib-resistant mutations: PDGFRA D842V mutation confers primary resistance to imatinib

The molecular testing should include:

• KIT exons 9,11,13, and 17
• PDGFRA exons 12 and 18
• If KIT/PDGFRA wild-type: Consider BRAF, KRAS, NRAS mutations and SDHB immunohistochemistry 1

Risk Stratification Requirements

Obtain the following pathological parameters to determine risk category:

• Tumor size (maximum diameter in cm)
• Mitotic count (expressed per 5 mm² area, not per HPF)
• Anatomic location (gastric vs. small intestinal vs. other)
• Presence of tumor rupture (spontaneous or surgical)

Treatment Algorithm

For Localized, Resectable GIST:

1. Small tumors (<2 cm gastric): Consider active surveillance with short-term reassessment at 3 months, then extended intervals if stable 2

2. Tumors ≥2 cm or rectal location: Surgical resection is standard, performed by surgeons trained in sarcoma management at specialized centers 1, 2

3. Large tumors requiring complex surgery (e.g., multivisceral resection, total gastrectomy):

   • Do NOT proceed directly to surgery
   • Obtain molecular analysis first to exclude imatinib-resistant mutations
   • Consider neoadjuvant imatinib to downstage the tumor and reduce surgical morbidity 1

For Metastatic or Unresectable GIST:

1. First-line: Imatinib 400 mg daily (if KIT exon 11 mutation or wild-type)
2. KIT exon 9 mutation: Consider higher dose imatinib 800 mg daily
3. PDGFRA D842V mutation: Imatinib will not work—consider avapritinib or clinical trial

Adjuvant Therapy Considerations:

For moderate to high-risk resected GISTs (based on size, mitotic rate, location, and rupture status), adjuvant imatinib therapy should be considered. Duration depends on risk stratification (typically 3 years for high-risk disease).

Critical Pitfalls to Avoid

1. Do not delay molecular testing: Waiting until after surgery or disease progression is a missed opportunity for optimal treatment planning 1, 2

2. Do not perform excisional biopsy on large tumors: Core needle biopsy (EUS-guided or percutaneous) is safer and provides adequate tissue for diagnosis and molecular analysis 1, 2

3. Do not assume all GISTs respond to imatinib: Approximately 15-20% are KIT/PDGFRA wild-type and may require alternative approaches 1

4. Do not use Ki-67 for risk stratification: Mitotic count per 5 mm² is the validated prognostic parameter, not Ki-67 2

5. Ensure molecular testing is performed at a centralized laboratory enrolled in external quality assurance programs with expertise in GIST 1, 2